A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Trial Profile

A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Idarucizumab (Primary)
  • Indications Blood coagulation disorders; Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Acronyms RE-VERSE AD
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Results (n=301) of sub-analysis assessing efficacy and safety of Idarucizumab in patient with gastrointestinal (GI) bleeding, were presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 13 Nov 2017 Results published in the Boehringer Ingelheim Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top